Being supported by decades of literature, it is clear that DNA damage repair deficiencies are a driver of PARP inhibitor sensitivity, but certainly considered in the context of pediatric cancers, this is evidently an incomplete explanation. This evidence concerns the gene PARP1 and cancer.